Immunovia AB (IMMNOV) fair value: what the stock is really worth
As of Oct 13, 2026: fair value of Immunovia AB SEK 0.07, price SEK 0.08, upside -15.0%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual.
Show more
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Stock analysis
Immunovia AB (IMMNOV) currently trades at kr 0.0800, while our model-based Fair Value estimate is kr 0.0680, 15.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: kr 0.0544 (bear) to kr 0.0884 (bull), the price of kr 0.0800 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Immunovia AB reported revenue of 685K SEK in FY2025 versus 844K SEK in FY2021, a compound −5.1%/yr. Reported net income was −146M SEK in FY2025.
Key figures
Market cap 53.8M SEK (≈ $5.4M) · P/S ratio 42.0 · EPS (TTM) kr −0.1400 · Return on equity −427% · Return on assets (EBIT) −164% · Operating margin −6,011% · Revenue (TTM) 1.2M SEK · Revenue growth (YoY) +323%.
What moves the price
The share trades about 77% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −15%, IMMNOV screens richer than that median.
Fair Value models
Bear kr 0.0544Fair Value kr 0.0680Bull kr 0.0884
Price kr 0.0800 · Upside -15.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−26.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37,203.9% (2020) → −11,606.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 127 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside+0.0% · Above median
Profitability
Return on assets−124.9% · Bottom 25%
Growth and dividend
Revenue growth323.3% · Top 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Immunovia AB Fair Value". https://www.fairvalue-calculator.com/stock/IMMNOV
Frequently asked questions
Is Immunovia AB (IMMNOV) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of kr 0.0680 versus a price of kr 0.0800, about −15% upside (overvalued).
What is the fair value of IMMNOV?
Our model-based fair value for Immunovia AB is kr 0.0680 (as of Oct 14, 2026), built from audited fundamentals. The current price: kr 0.0800.
What is the quality score of IMMNOV?
Immunovia AB has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Immunovia AB (IMMNOV)?
Our model-based price target is the fair value of kr 0.0680 (as of Oct 14, 2026) from 1 valuation models. Cautious scenario kr 0.0544, optimistic scenario kr 0.0884. It is a calculation from audited fundamentals, not an analyst target.
What is the Immunovia AB stock forecast for 2026?
Our models put fair value at kr 0.0680, about −15% upside versus a price of kr 0.0800 (overvalued). Cautious scenario kr 0.0544, optimistic scenario kr 0.0884. The calculation is refreshed regularly with new filings.
What is the revenue of Immunovia AB (IMMNOV)?
Immunovia AB reported trailing-twelve-month revenue of about 1.2M SEK (latest available figure, as of Oct 14, 2026).
What is the intrinsic value of Immunovia AB (IMMNOV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Immunovia AB it is kr 0.0680 per share (as of Oct 14, 2026), against a price of kr 0.0800. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Immunovia AB stock overvalued or undervalued in 2026?
As of Oct 14, 2026, IMMNOV trades above its calculated fair value: price kr 0.0800, fair value kr 0.0680, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMMNOV?
No. The price is what the market pays today (kr 0.0800); the fair value is what the company's own numbers justify (kr 0.0680). For Immunovia AB the two are kr 0.0120 per share apart. That gap is exactly why we show both numbers side by side.
How much is Immunovia AB worth?
The market values Immunovia AB at about 53.8M SEK (market capitalisation, as of Oct 14, 2026). Per share that is kr 0.0800; our models calculate a fair value of kr 0.0680 per share.
What do the bullish and bearish scenarios say about IMMNOV?
Our models span a range for Immunovia AB: cautious scenario kr 0.0544, base kr 0.0680, optimistic kr 0.0884 per share (as of Oct 14, 2026, price kr 0.0800). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Immunovia AB (IMMNOV)?
Balance-sheet figures for Immunovia AB (as of Oct 14, 2026): return on equity −427.0%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is IMMNOV from its 52-week high?
Immunovia AB trades at kr 0.0800, about 77% below its 52-week high of kr 0.3420 and 30% above the low of kr 0.0614 (as of Oct 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0680 is for.
Which stocks are comparable to Immunovia AB?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Immunovia AB stock attractive at the current price?
The data as of Oct 14, 2026: price kr 0.0800, calculated fair value kr 0.0680 (−15%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IMMNOV calculated?
We run Immunovia AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0680, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Immunovia AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Immunovia AB (IMMNOV)?
The closing price on Oct 13, 2026 was kr 0.0800. Our model-based fair value is kr 0.0680, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Immunovia AB right now?
Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Immunovia AB
How large is the market capitalisation of Immunovia AB (IMMNOV)?
The market capitalisation of Immunovia AB is 53.8M SEK (≈ $5.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Immunovia AB (IMMNOV)?
The price-to-sales ratio of Immunovia AB is 42.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Immunovia AB (IMMNOV)?
Earnings per share at Immunovia AB are kr −0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Immunovia AB (IMMNOV)?
The return on equity (ROE) of Immunovia AB is −427% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Immunovia AB (IMMNOV)?
On an EBIT basis the return on assets of Immunovia AB is −164% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Immunovia AB (IMMNOV)?
The operating margin of Immunovia AB is −6,011% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Immunovia AB (IMMNOV)?
Revenue at Immunovia AB is growing +323% versus a year earlier (3y avg −15.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Immunovia AB (IMMNOV) generate?
The free cash flow of Immunovia AB is −78.4M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Immunovia AB (IMMNOV) hold?
Immunovia AB holds more cash than debt, 76.6M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Immunovia AB in the live analysis
One click puts Immunovia AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 14, 2026